Clinical Trial Update: The Effects of Ambrisentan on Exercise Capacity in Fontan Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial assessed whether ambrisentan improves exercise capacity in Fontan patients with single-ventricle physiology; the study has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Single-ventricle Congenital Heart Disease

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Single Ventricle Fontan Palliation | Phase 4 | Status: COMPLETED | Results posted: 2018-05-07